35 related articles for article (PubMed ID: 36801702)
1. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.
Mustafa Ali MK; Corley EM; Alharthy H; Kline KAF; Law JY; Lee ST; Niyongere S; Duong VH; Emadi A; Baer MR
Front Oncol; 2022; 12():858202. PubMed ID: 35433414
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Zeidan AM; Pollyea DA; Borate U; Vasconcelos A; Potluri R; Rotter D; Kiendrebeogo Z; Gaugler L; Prebet T; Strocchia M; Bonifacio G; Chen C
Ann Hematol; 2023 Apr; 102(4):749-754. PubMed ID: 36732419
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).
Zeidan AM; Mearns ES; Ng CD; Shah A; Lamarre N; Yellow-Duke A; Alrawashdh N; Yang B; Cheng WH; Bui CN; Svensson A
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):177-186. PubMed ID: 37996264
[TBL] [Abstract][Full Text] [Related]
4. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Wang ES; Montesinos P; Minden MD; Lee JH; Heuser M; Naoe T; Chou WC; Laribi K; Esteve J; Altman JK; Havelange V; Watson AM; Gambacorti-Passerini C; Patkowska E; Liu S; Wu R; Philipose N; Hill JE; Gill SC; Rich ES; Tiu RV
Blood; 2022 Oct; 140(17):1845-1857. PubMed ID: 35917453
[TBL] [Abstract][Full Text] [Related]
5. Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons.
Tremblay G; Westley T; Cappelleri JC; Arondekar B; Chan G; Bell TJ; Briggs A
Clinicoecon Outcomes Res; 2019; 11():551-565. PubMed ID: 31564931
[TBL] [Abstract][Full Text] [Related]
6. Low-dose decitabine for previously untreated acute myeloid leukemia ineligible for intensive chemotherapy aged 65 years or older: a prospective study based on comprehensive geriatric assessment.
Feng R; Zhang S; Li JT; Wang T; Zhang CL; Bai JF; Yang L; Wang LR; Jing HM; Liu H
Ther Adv Hematol; 2023; 14():20406207231208979. PubMed ID: 38033755
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
Almeida AM; Prebet T; Itzykson R; Ramos F; Al-Ali H; Shammo J; Pinto R; Maurillo L; Wetzel J; Musto P; Van De Loosdrecht AA; Costa MJ; Esteves S; Burgstaller S; Stauder R; Autzinger EM; Lang A; Krippl P; Geissler D; Falantes JF; Pedro C; Bargay J; Deben G; Garrido A; Bonanad S; Diez-Campelo M; Thepot S; Ades L; Sperr WR; Valent P; Fenaux P; Sekeres MA; Greil R; Pleyer L
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420120
[TBL] [Abstract][Full Text] [Related]
8. Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial.
Montesinos P; Sossa-Melo C
Lancet Haematol; 2023 Nov; 10(11):e866-e867. PubMed ID: 37914474
[No Abstract] [Full Text] [Related]
9. Indirect treatment comparison of oral versus injectable azacitidine as maintenance therapy for acute myeloid leukemia.
Tabah A; Huggar D; Wang ST; Johnson SJ; Copher RM; O'Connell T; McBride A; LeBlanc TW
Future Oncol; 2022 Dec; ():. PubMed ID: 36507931
[TBL] [Abstract][Full Text] [Related]
10. Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine.
Kim M; Ahn SY; Kim T; Jung SH; Song GY; Yang DH; Lee JJ; Kim MY; Park JH; Shin MG; Ahn JS; Kim HJ; Kim DDH
Hematology; 2024 Dec; 29(1):2324417. PubMed ID: 38433437
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP).
Delia M; Carluccio P; Buquicchio C; Vergine C; Greco G; Amurri B; Melpignano A; Melillo L; Cascavilla N; Guarini A; Capalbo S; Tarantini G; Mazza P; Pavone V; Di Renzo N; Specchia G
Leuk Res; 2015 Aug; ():. PubMed ID: 26364798
[TBL] [Abstract][Full Text] [Related]
12. Oral decitabine plus cedazuridine versus intravenous decitabine.
de Witte T
Lancet Haematol; 2024 Jan; 11(1):e2-e3. PubMed ID: 38135372
[No Abstract] [Full Text] [Related]
13. Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies.
Woost PG; William BM; Cooper BW; Ueda Oshima M; Otegbeye F; De Lima MJ; Wald D; Mahfouz RZ; Saunthararajah Y; Stefan T; Jacobberger JW
Cytometry B Clin Cytom; 2024 Jan; 106(1):11-24. PubMed ID: 38345160
[TBL] [Abstract][Full Text] [Related]
14. Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
Didi I; Alliot JM; Dumas PY; Vergez F; Tavitian S; Largeaud L; Bidet A; Rieu JB; Luquet I; Lechevalier N; Delabesse E; Sarry A; De Grande AC; Bérard E; Pigneux A; Récher C; Simoncini D; Bertoli S
Leuk Res; 2024 Jan; 136():107437. PubMed ID: 38215555
[TBL] [Abstract][Full Text] [Related]
15. Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study.
Rodríguez-Medina C; Martínez-Cuadrón D; Cano I; Gil C; Tormo M; Del Pilar Martínez-Sánchez M; Del Castillo TB; Serrano-López J; Benavente C; Herrera-Puente P; García-Boyero R; Lavilla-Rubira E; Amigo ML; Sayas-Lloris M; Bergua-Burgues JM; Pérez-Simón JA; Rodríguez G; Espadana A; Vidriales-Vicente B; Fernández R; López-Lorenzo JL; López M; García-Fortes M; Labrador Gómez J; Colorado-Araujo M; Sossa-Melo CL; Aguilar E; Montesinos Fernández P
Leuk Res; 2020 Mar; 92():106352. PubMed ID: 32240863
[TBL] [Abstract][Full Text] [Related]
16. Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy.
Maurillo L; Spagnoli A; Candoni A; Papayannidis C; Borlenghi E; Lazzarotto D; Fianchi L; Sciumè M; Zannier ME; Buccisano F; Del Principe MI; Mancini V; Breccia M; Fanin R; Todisco E; Lunghi M; Palmieri R; Fracchiolla N; Musto P; Rossi G; Venditti A
Leuk Res; 2023 Apr; 127():107040. PubMed ID: 36801702
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.
Kwag D; Cho BS; Bang SY; Lee JH; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Blood Cancer J; 2022 Dec; 12(12):169. PubMed ID: 36529771
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
